Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
Amiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or wi...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Case Reports in Medicine |
Online Access: | http://dx.doi.org/10.1155/2014/231651 |
id |
doaj-5fb9bc4a3d8343d2adad2606da0a7b58 |
---|---|
record_format |
Article |
spelling |
doaj-5fb9bc4a3d8343d2adad2606da0a7b582020-11-24T23:12:21ZengHindawi LimitedCase Reports in Medicine1687-96271687-96352014-01-01201410.1155/2014/231651231651Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic ChallengeUmang Barvalia0Barkha Amlani1Ram Pathak2Department of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USADepartment of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USADepartment of Endocrinology, Marshfield Clinic, Marshfield, WI 54449, USAAmiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or without preexisting thyroid disease. Amiodarone-induced thyrotoxicosis (AIT) is a clinically recognized condition commonly due to iodine-induced excessive synthesis of thyroid, also known as type 1 AIT. In rare instances, AIT is caused by amiodarone-induced inflammation of thyroid tissue, resulting in release of preformed thyroid hormones and a hyperthyroid state, known as type 2 AIT. Distinguishing between the two states is important, as both conditions have different treatment implications; however, a mixed presentation is not uncommon, posing diagnostic and treatment challenges. We describe a case of a patient with amiodarone-induced type 2 hyperthyroidism and review the current literature on the best practices for diagnostic and treatment approaches.http://dx.doi.org/10.1155/2014/231651 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Umang Barvalia Barkha Amlani Ram Pathak |
spellingShingle |
Umang Barvalia Barkha Amlani Ram Pathak Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge Case Reports in Medicine |
author_facet |
Umang Barvalia Barkha Amlani Ram Pathak |
author_sort |
Umang Barvalia |
title |
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge |
title_short |
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge |
title_full |
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge |
title_fullStr |
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge |
title_full_unstemmed |
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge |
title_sort |
amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge |
publisher |
Hindawi Limited |
series |
Case Reports in Medicine |
issn |
1687-9627 1687-9635 |
publishDate |
2014-01-01 |
description |
Amiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or without preexisting thyroid disease. Amiodarone-induced thyrotoxicosis (AIT) is a clinically recognized condition commonly due to iodine-induced excessive synthesis of thyroid, also known as type 1 AIT. In rare instances, AIT is caused by amiodarone-induced inflammation of thyroid tissue, resulting in release of preformed thyroid hormones and a hyperthyroid state, known as type 2 AIT. Distinguishing between the two states is important, as both conditions have different treatment implications; however, a mixed presentation is not uncommon, posing diagnostic and treatment challenges. We describe a case of a patient with amiodarone-induced type 2 hyperthyroidism and review the current literature on the best practices for diagnostic and treatment approaches. |
url |
http://dx.doi.org/10.1155/2014/231651 |
work_keys_str_mv |
AT umangbarvalia amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge AT barkhaamlani amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge AT rampathak amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge |
_version_ |
1725601221493915648 |